摘要
目的:探讨对精神分裂症患者采取帕利哌酮缓释片联合奥氮平治疗的效果。方法:在2016年1月到2018年1月期间来我院就诊的精神分裂症患者中选取48例参与本组研究,按照奇偶分组法将其均分2组,各24例。对参照组采取奥氮平进行治疗,对实验组采取奥氮平联合帕利哌酮缓释片进行治疗。分析48例精神分裂症患者的PANSS评分、BPRS评分、临床疗效和安全性。结果:实验组患者的PANSS评分、BPRS评分相比于参照组均较高,组间数据对比差异显著(p<0.05);与实验组相比较,参照组临床疗效较低、不良反应发生率较高,组间数据行卡方检验,差异性显著(p<0.05)。结论:对精神分裂症患者采取帕利哌酮缓释片联合奥氮平治疗,具有较高的安全性和临床疗效,患者的精神状态得到明显改善,值得临床上广泛应用。
Objective:To discuss the effect of treating schizophrenia patients with paliperidone extended-release tablets combining olanzapine.Methods:Choosed 48 cases of schizophrenia patients from Jan.2016 to Jan.2018 to divide into study group and controlled group with 24 cases in each.The controlled group were treated with olanzapine,the study group were treated with paliperidone extended-release tablets combining olanzapine.Compared the PANSS scores,BPRS scores,safety and effect.Results:The results PANSS socres and BPRS scores of study group was higher than controlled group(P<0.05).And the incidence of study group was lower than controlled group(P<0.05).Conclusion:Using paliperidone extended-release tablets combining olanzapine to treat schizophrenia patients is effective to extend in clinic.
出处
《湖南中医药大学学报》
CAS
2018年第A01期56-56,共1页
Journal of Hunan University of Chinese Medicine
关键词
精神分裂症
帕利哌酮缓释片
奥氮平
安全性
schizophrenia
paliperidone extended-release tablets
olanzapine
safety
